In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tufts University

www.tufts.edu

Latest From Tufts University

Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.

Clinical Trials Research and Development Strategies

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals

Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?

2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

BioPharmaceutical Business Strategies

Can Artificial Intelligence Help Find Better Medicines?

Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.

BioPharmaceutical Innovation
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register